ArticleMedComm2025
Exosomal Long Interspersed Nuclear Element-1 Analytes Discriminate Histologic Subtypes, Sex, and Clinicopathological Characteristics of Patients with Non-Small Cell Lung Cancer.
Article in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Urinary Profiles of Exosomal LINE-1 mRNA and Associated miRNAs in Non-Small-Cell Lung Cancer.Cells · 2026Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
Abstract
Lung cancer is the leading cause of cancer-related mortality worldwide, with lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD) representing the most common non-small cell lung cancer (NSCLC) subtypes. The invasive procedures typically required to obtain specimens for clinical evaluation pose significant risks and can delay patient care. To address these limitations, analysis of cancer-related biomarkers in circulating exosomes has emerged as a promising liquid biopsy approach. In this study, levels of long interspersed nuclear element-1 (LINE-1) mRNA were measured in ostensibly healthy controls and compared with those in patients with LUSC and LUAD. Both LINE-1 ORF1 and ORF2 mRNA were readily detectable across all cancer stages in both female and male patients, with expression patterns correlating with histologic subtype, tumor stage, tumor size, lymph node involvement, distant metastasis, and smoking status. Receiver operating characteristic analyses confirmed the robustness of this approach in distinguishing NSCLC subtypes and associated clinicopathological features. Collectively, these findings highlight exosomal LINE-1 mRNA as a readily accessible biomarker for precision profiling of NSCLC. The strong diagnostic and prognostic performance of this liquid biopsy platform underscores its potential to advance the clinical management of patients with NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.